BERGER FRANKLIN M — SEC insider filings

SEC reporting owner CIK 1273885. 46 insider filings on record with FilingPulse; latest filed 2026-10-13.

Transaction summary — filings shown

Covers all 46 filings on record, filed 2020-10-30 to 2026-10-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Rain Oncology Inc. (RAIN)Director86 legs · 293,667 sh · $3,410,826—11
ESSA Pharma Inc. (EPIX)Director94 legs · 156,730 sh · $2,091,9357 legs · 272,840 sh · $729,05215
Atea Pharmaceuticals, Inc. (AVIR)Director135 legs · 91,666 sh · $1,162,9813 legs · 401,272 sh · $1,238,15923
Kezar Life Sciences, Inc. (KZR)Director93 legs · 80,000 sh · $1,299,800—21
Retension Pharmaceuticals, Inc. (RTSN)Director31 leg · 10,000 sh · $120,000—3
FIVE PRIME THERAPEUTICS, INC. (FPRX)Director1——6
Atreca, Inc. (BCEL)Director3——3

Insider filings — BERGER FRANKLIN M

FiledFormIssuerReported transactionsSource
2026-10-134Retension Pharmaceuticals, Inc. (RTSN)Conversion (C): 12,517 · Purchase (P): 10,000 @ $12 · Conversion (C): 12,517 (derivative)EDGAR
2026-10-083Retension Pharmaceuticals, Inc. (RTSN)Holdings only — no transactions reportedEDGAR
2026-10-084Retension Pharmaceuticals, Inc. (RTSN)Grant/award (A): 5,636 (derivative) @ $0EDGAR
2026-06-234Atea Pharmaceuticals, Inc. (AVIR)Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0EDGAR
2026-05-114Kezar Life Sciences, Inc. (KZR)Code (U): 89,069 · Disposition to issuer (D): 3,500 (derivative) @ $0 · Disposition to issuer (D): 5,000 (derivative) @ $0 · Disposition to issuer (D): 5,000 (derivative) @ $0 · Disposition to issuer (D): 2,600 (derivative) @ $0 · Disposition to issuer (D): 2,600 (derivative) @ $0EDGAR
2025-10-154ESSA Pharma Inc. (EPIX)Disposition to issuer (D): 784,404EDGAR
2025-06-244Atea Pharmaceuticals, Inc. (AVIR)Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0EDGAR
2025-06-234Kezar Life Sciences, Inc. (KZR)Grant/award (A): 5,000 (derivative) @ $0EDGAR
2025-01-174/AAtea Pharmaceuticals, Inc. (AVIR)Purchase (P): 15,000 @ $3.19 · Purchase (P): 10,000 @ $3.36EDGAR
2025-01-174Atea Pharmaceuticals, Inc. (AVIR)Purchase (P): 15,000 @ $3.19 · Purchase (P): 10,000 @ $3.36EDGAR
2024-12-124Atea Pharmaceuticals, Inc. (AVIR)Sale (S): 359,606 @ $2.85EDGAR
2024-06-214Atea Pharmaceuticals, Inc. (AVIR)Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0EDGAR
2024-06-214Kezar Life Sciences, Inc. (KZR)Grant/award (A): 50,000 (derivative) @ $0EDGAR
2024-06-184Atea Pharmaceuticals, Inc. (AVIR)Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0EDGAR
2024-03-284ESSA Pharma Inc. (EPIX)Grant/award (A): 50,000 (derivative) @ $0EDGAR
2024-01-264Rain Oncology Inc. (RAIN)Code (U): 1,005,207 · Disposition to issuer (D): 35,000 (derivative) · Disposition to issuer (D): 24,000 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2023-11-224ESSA Pharma Inc. (EPIX)Purchase (P): 23,259 @ $5.73EDGAR
2023-11-164ESSA Pharma Inc. (EPIX)Purchase (P): 60,000 @ $5.35 · Purchase (P): 16,471 @ $5.99EDGAR
2023-08-114Rain Oncology Inc. (RAIN)Grant/award (A): 35,000 (derivative) @ $0EDGAR
2023-07-264Kezar Life Sciences, Inc. (KZR)Disposition to issuer (D): 26,000 (derivative) · Grant/award (A): 26,000 (derivative) · Disposition to issuer (D): 26,000 (derivative) · Grant/award (A): 26,000 (derivative)EDGAR
2023-06-214Atea Pharmaceuticals, Inc. (AVIR)Grant/award (A): 33,150 (derivative) @ $0 · Grant/award (A): 46,750 (derivative) @ $0EDGAR
2023-06-164Kezar Life Sciences, Inc. (KZR)Grant/award (A): 35,000 (derivative) @ $0EDGAR
2023-06-154Atreca, Inc. (BCEL)Grant/award (A): 12,000 (derivative) @ $0EDGAR
2023-01-054ESSA Pharma Inc. (EPIX)Sale (S): 25,000 @ $3 · Sale (S): 32,000 @ $2.90 · Sale (S): 50,000 @ $2.86 · Sale (S): 50,000 @ $2.67 · Sale (S): 43,617 @ $2.53 · Sale (S): 37,889 @ $2.41 · +1 moreEDGAR
2022-11-234Rain Therapeutics Inc. (RAIN)Purchase (P): 45,000 @ $7.80 · Purchase (P): 77,000 @ $8.27EDGAR
2022-11-154Atea Pharmaceuticals, Inc. (AVIR)Sale (S): 25,500 @ $5.15 · Sale (S): 16,166 @ $5.16EDGAR
2022-11-144Rain Therapeutics Inc. (RAIN)Purchase (P): 42,881 @ $5.83EDGAR
2022-11-014ESSA Pharma Inc. (EPIX)Grant/award (A): 22,500 (derivative) @ $0EDGAR
2022-08-194Rain Therapeutics Inc. (RAIN)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-214Atea Pharmaceuticals, Inc. (AVIR)Grant/award (A): 61,264 (derivative) @ $0EDGAR
2022-06-174Kezar Life Sciences, Inc. (KZR)Grant/award (A): 26,000 (derivative) @ $0EDGAR
2022-06-104Atreca, Inc. (BCEL)Grant/award (A): 12,000 (derivative) @ $0EDGAR
2022-03-224Kezar Life Sciences, Inc. (KZR)Purchase (P): 15,000 @ $15.96 · Purchase (P): 45,000 @ $17 · Purchase (P): 20,000 @ $14.77EDGAR
2021-09-234Rain Therapeutics Inc. (RAIN)Purchase (P): 3,786 @ $14.30EDGAR
2021-09-234Kezar Life Sciences, Inc. (KZR)Option exercise (M): 8,896 @ $5.91 · Option exercise (M): 8,896 @ $7.63 · Option exercise (M): 8,896 @ $5.60 · Option exercise (M): 8,896 (derivative) @ $0 · Option exercise (M): 8,896 (derivative) @ $0 · Option exercise (M): 8,896 (derivative) @ $0EDGAR
2021-06-304Kezar Life Sciences, Inc. (KZR)Grant/award (A): 26,000 (derivative) @ $0EDGAR
2021-06-214Atea Pharmaceuticals, Inc. (AVIR)Grant/award (A): 34,025 (derivative) @ $0EDGAR
2021-06-114Atreca, Inc. (BCEL)Grant/award (A): 12,000 (derivative) @ $0EDGAR
2021-05-184Rain Therapeutics Inc. (RAIN)Grant/award (A): 24,000 (derivative) @ $0EDGAR
2021-04-274Rain Therapeutics Inc. (RAIN)Purchase (P): 120,000 @ $17 · Purchase (P): 5,000 @ $15.78 · Conversion (C): 175,939 · Conversion (C): 535,601 · Conversion (C): 189,998 (derivative) @ $0 · Conversion (C): 578,397 (derivative) @ $0EDGAR
2021-04-194FIVE PRIME THERAPEUTICS, INC. (FPRX)Disposition to issuer (D): 5,000 @ $38 · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2021-03-044ESSA Pharma Inc. (EPIX)Purchase (P): 57,000 @ $27EDGAR
2021-01-264/AESSA Pharma Inc. (EPIX)Grant/award (A): 16,500 (derivative) @ $0EDGAR
2021-01-114ESSA Pharma Inc. (EPIX)Option exercise (M): 1,716 @ $4 · Option exercise (M): 6,534 @ $4 · Option exercise (M): 2,184 @ $3.81 · Option exercise (M): 25,000 @ $3.23 · Option exercise (M): 6,773 @ $4.67 · Option exercise (M): 1,716 (derivative) @ $0 · +5 moreEDGAR
2020-11-034Atea Pharmaceuticals, Inc. (AVIR)Conversion (C): 759,606 · Purchase (P): 41,666 @ $24 · Conversion (C): 400,000 (derivative) · Conversion (C): 132,014 (derivative) · Conversion (C): 131,578 (derivative) · Conversion (C): 60,540 (derivative) · +1 moreEDGAR
2020-10-304Atea Pharmaceuticals, Inc. (AVIR)Grant/award (A): 80,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1273885 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs